Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• CAR T cells demonstrated cytolytic activity in controlling myeloma even with limited BCMA expression, highlighting therapeutic potential.
• The analysis revealed effective targeting of CD229 antigen by CAR T cell therapy, showing promise in multiple myeloma treatment.
• Co-culture experiments with K562 cell lines over 24 hours confirmed the specific activity of CAR T cells against CD229, supporting further research.
• This research suggests dual targeting of BCMA and CD229 may improve outcomes in myeloma, calling for further clinical validation.